Research advances in tenofovir in treatment of chronic hepatitis B patients with drug resistance
10.3969/j.issn.1001-5256.2016.11.041
- VernacularTitle:替诺福韦酯治疗核苷和核苷酸类药物耐药慢性乙型肝炎患者的研究进展
- Author:
Yuerong YAN
1
;
Jihong FENG
Author Information
1. Department of Infectious Diseases, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116044, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
drug resistance, viral;
tenofovir disoproxil fumarate;
review
- From:
Journal of Clinical Hepatology
2016;32(11):2182-2185
- CountryChina
- Language:Chinese
-
Abstract:
Currently, tenofovir is the first-line drug for the treatment of chronic hepatitis B. This article reviews the research advances in its therapeutic effects in patients who are resistant to lamivudine and adefovir dipivoxil, respond poorly to entecavir, or have multidrug resistance and introduces the results of the comparative study on the therapeutic effects of tenofovir monotherapy and combined treatment. It is pointed out that tenofovir has good safety and a good therapeutic effect in patients with drug resistance, including pregnant women; however, there are no significant differences in study results between tenofovir monotherapy and combined treatment.
